Placebo response in clinical trials of antipsychotic medications is highly heterogeneous and has implications for the design of placebo-controlled trials, according to a meta-analysis presented at the American Psychiatric Association 2010 Annual Meeting.
“Placebo response is often observed in psychiatric randomized clinical trials, and it presents a challenge for psychopharmacologic drug development,” said principal study author Ofer Agid, MD, University of Toronto, Ontario, Canada, and the Centre for Addiction and Mental Health. “We found there are differences in the placebo response in studies. We tried to understand if there are predictors.”
Reported by Caroline Helwick
Medscape Medical News
Submitted by SARDAA